Effects of agents which elevate cyclic AMP on guinea-pig eosinophil homotypic aggregation
Open Access
- 1 August 1996
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 118 (8) , 2099-2106
- https://doi.org/10.1111/j.1476-5381.1996.tb15649.x
Abstract
1 Eosinophil recruitment and activation in inflamed tissue is thought to play an important role in the pathophysiology of allergic diseases. Experimental evidence suggests that elevating cyclic AMP is an effective means of reducing eosinophil recruitment in vivo and may therefore have therapeutic benefit. In the present study, we have assessed the capacity of cyclic AMP-elevating agents to modulate guinea-pig eosinophil homotypic aggregation, a CD18-dependent process, which may be an important component of eosinophil function in vivo. 2 Prostaglandin E1 (PGE1, 10−10 to 10−6 m) inhibited platelet activating-factor (PAF)- and C5a-induced eosinophil aggregation in a concentration-dependent manner. However, PAF-induced responses were more potently and more effectively inhibited by PGE1. The inhibitory effects of PGE1 on PAF-induced aggregation were reversed by pretreatment of eosinophils with the protein kinase A inhibitors H89 and KT5720. 3 The β2-adrenoceptor agonists, salbutamol and salmeterol, concentration-dependently inhibited eosinophil aggregation induced by C5a and PAF and, again, PAF-induced responses were more effectively reduced. The inhibitory effect of salmeterol was mediated by β-adrenoceptors, as assessed by the reversal after pretreatment with propranolol. 4 Rolipram, a selective phosphodiesterase 4 (PDE4) inhibitor, also attenuated PAF- and C5a-induced aggregation and at a low concentration which did not affect aggregation per se, had a synergistic effect with PGE1 and salbutamol to suppress this response. 5 Activation of eosinophils with PAF or C5a induced a small but significant increase in the level of CD18 expression on the eosinophil surface. PGE1 (10−7 m) decreased PAF- and C5a-induced upregulation of CD18 by 93% and 62%, respectively. 6 These results demonstrate that cyclic AMP-elevating agents effectively inhibit eosinophil aggregation, a CD18-dependent functional response. Because CD18 has been shown to be important for eosinophil recruitment to inflamed tissue in vivo, our findings may be of relevance to the efficacy of cyclic AMP-elevating agents at inhibiting eosinophil trafficking.Keywords
This publication has 43 references indexed in Scilit:
- Mechanisms of human eosinophil activation by complement protein C5a and platelet‐activating factor: similar functional responses are accompanied by different morphologic alterationsAllergy, 1995
- The dynamic regulation of integrin adhesivenessCurrent Biology, 1994
- Formation of eosinophilic and monocytic intradermal inflammatory sites in the dog by injection of human RANTES but not human monocyte chemoattractant protein 1, human macrophage inflammatory protein 1 alpha, or human interleukin 8.The Journal of Experimental Medicine, 1993
- The Biology of the Eosinophilic LeukocyteAnnual Review of Medicine, 1993
- T cells and eosinophils in the pathogenesis of asthmaImmunology Today, 1992
- Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.Thorax, 1991
- Characteristics of CR3-mediated aggregation in human eosinophils: Effect of priming by platelet-activating factorJournal of Allergy and Clinical Immunology, 1991
- T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1Nature, 1989
- Formation of Oedema and Accumulation of Eosinophils in the Guinea Pig LungInternational Archives of Allergy and Immunology, 1989
- Terbutaline modulation of human allergic skin reactionsJournal of Allergy and Clinical Immunology, 1983